Biohemp International Inc. (fka BKIT)

[WALL STREET KID]

Wolf Did Paid BKIT Promo After Hours



BKIT HAS DELIVERED 68% TOTAL GAINS!
COULD IT BREAKOUT AGAIN TOMORROW?


Good Evening HeyWood JaBlowMe and Wolfpack Members,



BKIT (Blake Insomnia Therapeutics, Inc) is BACK as my New Alert!
Last Price: 1.05 | SEC Filings | Latest News

Begin your research at http://www.blakeinsomnia.com


Tonight we take another look at one of our most successful profiles of 2017 as it pops back to the top of our radar!

BKIT IS BACK ON BREAKOUT ALERT!

The last two times we covered BKIT, Wolfpack members saw extraordinary multi-day rallies which delivered up to 68% TOTAL GAINS!

After some profit taking by traders in the last month, BKIT's price has declined to Cheaper than Ever levels for us.

However with some recent Landmark News regarding the closing of it's Joint Venture (more info below), BKIT has come back to life and shattered it's downtrend with all indicators screaming BULLISH!

Take a look....




BKIT is a pharmaceutical company devoted to improving nighttime and daytime quality of life for people with insomnia via their patent-pending compound, Zleepax™ (ZLX-1).

BKIT has been creating quite the buzz on the Street as it looks to tackle one of humankind's most precious activities...SLEEP - with what some call a "revolutionary" sleeping aid with no side-effects!

The company claims Zleepax™ has demonstrated efficacy without causing side effects identified as the No. 1 problem with current sleep medication.

As you can imagine, the market for a drug like this is TREMENDOUS as somewhere between 50 and 70 million Americans suffer from sleep disorders, according to the CDC, and 9 million individuals in the U.S. taking prescription sleep medicine.


BKIT - READY TO CONQUER INSOMNIA?
The pharmaceutical market has been DEMANDING a "non-drowsy"/no side-effect sleep aid for years.

Sadly, our options that are currently on the market can either be outright dangerous or cause nausea, stomach pain, sleep disorders, headaches, reduced memory, daytime "hangover" and more.

And now, for the first time, this one little-known company may have found the formula.

Blake Insomnia Therapeutics (OTC: BKIT), is a Pharmaceutical Startup that claims it has created the world's first sleeping pill based on Beta Blockers!


WHY BETA BLOCKERS?
For decades, beta blockers have been used as anti-depressants - reducing sleep quality due to reduced melatonin levels in the brain - the chemical that tells your brain to "go to sleep".

It's only now that mainstream science is starting to realize the power that beta blockers possess as sleep aids.

BKIT has access to a formula that no other company has: a Compound Called ZLX-1

ZLX-1 is a beta blocker...a compound that prevents the brain from absorbing adrenaline and related compounds.

And from ZLX-1 comes BKIT's Zleepax™ - the first sleep aid with beta blockers as the major active agent. As they explain:

First generation beta blockers inhibited natural melatonin secretion and had a negative impact on sleep. Recent publications have shown that certain third-generation beta blockers actually improve quality of sleep for patients with mild hypertension.

These third-generation beta blockers has been widely used to treat hypertension since the early 1990s, is well tolerated in chronic use, has an attractive side-effect profile, and should thus perform excellently applied as a sleep enhancer. Our patent application covers the use of beta blockers such as Nebivolol—alone or in combination with other anti-insomnia drugs—for the treatment of stress-related insomnia.

For example, Stress is one of the most common causes of insomnia.

Where traditional hypnotics “force” people to sleep by depressing the central nervous system, Zleepax acts by diminishing the physical symptoms of stress that keep people awake at night.

And what about that "Daytime Hangover"?

Based on beta blockers, Zleepax dramatically reduces these and many other unwanted side effects. This means that, in stark contrast to existing hypnotics, Zleepax should be able to give many patients a better night’s sleep with fewer of the side effects they do not want.


HERE'S THE BEST PART....
The research and development phase or Zleepax, BKIT's flagship product, is nearly complete.

But BKIT may have sort of a "fast-track to approval".

According to this article, Phase I studies are not necessary since the active ingredient of the drug is an established beta blocker.

So this removes a large portion of the time and costs associated with getting it to market.

"Phase II studies will kick off this year and should be completed in mid to late 2018. The target is to enroll between 75 to 300 patients, something that Blake should have no problem doing based on the incidence rate of this condition, and the endpoints will revolve around safety and clinical benefit. A phase III study will follow, enrolling around 300 patients, and will target cementing the efficacy profile of Zleepax. Commercialization, assuming the trials run smoothly, should come in 2019."


UPDATE: BKIT CLOSES JOINT VENTURE!

Blake Insomnia Therapeutics Inc. Closes Joint Venture with Sajo Consulting LLC

NEW YORK, Feb. 25, 2017 -- Blake Insomnia Therapeutics Inc. (BKIT) and Sajo Consulting LLC are pleased to announce completion of a joint venture agreement for the development and commercialization of a series of oral products to aid in the treatment of insomnia. The joint venture intends to develop products to treat transient insomnia using Blake’s proprietary Zleepax™ formula.

Clinical trials are planned for Q2 2017 pending approval of a New Drug Application in Canada with US and International submissions to follow later.

About Sajo Consulting LLC
Sajo designs solutions and strategies in getting products to market faster and smarter. Their research, scientific, regulatory and operational team puts best practice standards to work while building innovative solutions for constantly evolving industries.



THE BOTTOM LINE
With a potential bottom bounce chart and a potentially revolutionary aid for insomnia, BKIT may be a company you won't be able to ignore going forward.

Already we've seen it's tremendous gain potential! Could it rally once again tomorrow?

If you missed BKIT the last two times, DO NOT miss it this time!

Make sure you put BKIT on your screen TOMORROW MORNING and Follow on Twitter for all the Updates + Play-by-Play!

Good Trading,

Richard "The Wolf" Ellis
www.thewolfofpennystocks.com




This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. The paying party may own shares and may liquidate them during the promotional period.

PLEASE NOTE WELL: TheWolfofPennyStocks.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice.

THEWOLFOFPENNYSTOCKS.COM WILL NEVER ACCEPT FREE OR RESTRICTED TRADING SHARES IN ANY COMPANIES MENTIONED at THEWOLFOFPENNYSTOCKS.COM &/OR ANY OF OUR SOCIAL NETWORKING AND EMAIL ADVERTISING PLATFORMS.

You are reading this newsletter because you have subscribed via our Opt-In Signup form on our Website. If you have been subscribed by mistake, you may unsubscribe [[manage_your_subscriptions_url]]HERE.

This Newsletter is now owned and operated by Link Media. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to Link Media and/or it's subscriber base. Our website and newsletter are for Entertainment purposes only. This newsletter is NOT a source of unbiased information. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list. Full disclaimer can be read at http://www.TheWolfofPennyStocks.com/disclaimer

We encourage all to read the SEC INVESTOR ALERT before reading our Newsletter.

Release of Liability: Through use of this email and/or website advertisement viewing or using you agree to hold TheWolfofPennyStocks.com, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. TheWolfofPennyStocks.com sponsored advertisements do not purport to provide an analysis of any company's financial position, operations or prospects and this is not to be construed as a recommendation by TheWolfofPennyStocks.com or an offer or solicitation to buy or sell any security.

COMPENSATION: TheWolfofPennyStocks.com has been compensated thirty-five thousand dollars cash via bank wire by a third party, Sierra Publishing, Inc. for a one day Blake Insomnia Therapeutics Inc. advertising services contract. TheWolfofPennyStocks.com does not own any shares of BKIT. TheWolfofPennyStocks.com has been previously compensated a total of ninety thousand dollars cash via bank wire by a third party, Sierra Publishing, Inc. for two one day Blake Insomnia Therapeutics Inc. advertising services contracts which have expired. TheWolfofPennyStocks.com does not investigate the background of any third party. The third party may have shares and may liquidate it, which may negatively affect the stock price. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. TheWolfofPennyStocks.com may purchase shares on the open market of any mentioned company following the dissemination of this email. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TheWolfofPennyStocks.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and TheWolfofPennyStocks.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Further, TheWolfofPennyStocks.com has no advance knowledge of any future events of the profiled companies which includes, but is not limited to, news & press releases, changes in corporate structure, or changes in share structure.

None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TheWolfofPennyStocks.com strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TheWolfofPennyStocks.com is compliant with the Can Spam Act of 2003. TheWolfofPennyStocks.com does not offer such advice or analysis, and TheWolfofPennyStocks.com further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a 'safe harbor' in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be "forward looking statements". Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as "projects", "foresee", "expects", "will", "anticipates", "estimates", "believes", "understands", or that by statements indicating certain actions "may", "could", or "might" occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security's previous day closing price and the high of day price during our promotional coverage.

In preparing this publication, TheWolfofPennyStocks.com has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, TheWolfofPennyStocks.com and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TheWolfofPennyStocks.com is not responsible for any claims made by the companies advertised herein, nor is TheWolfofPennyStocks.com responsible for any other promotional firm, its program or its structure.